Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Carvykti
Biotech
ASH: Gilead-Arcellx data build CAR-T's case in advanced myeloma
Arcellx's new data on a Gilead-partnered CAR-T show durable results and best-in-class potential for advanced multiple myeloma, analysts said.
Gabrielle Masson
Nov 5, 2024 3:08pm
J&J's multiple myeloma combo produces 96% Carvykti-like response
Jun 5, 2023 2:16pm
J&J trims the edges of its pipeline, mum on timing of new data
Jan 24, 2023 10:54am
Janssen peels back layer of data on its new myeloma bispecifc
Dec 12, 2022 10:10am
CRISPR Tx's pipeline update fails to impress investors
Jun 22, 2022 11:35am
Precision hails early data of its ‘off-the-shelf’ CAR-T therapy
Jun 8, 2022 10:25am
